The Role of Transplant in Lymphoproliferative Disorders in the Era of Novel Agents

The content that follows is drawn from the presentation made by Dr. Kevin Song at the annual CCOLD 2016 meeting, and is augmented with perspectives from the CARE Hematology Faculty. To see the full CCOLD Report, please click here.

Transplantation is an important treatment used in many hematological malignancies. This includes multiple myeloma (MM), Hodgkin’s lymphoma (HL), and chronic lymphocytic leukemia (CLL). The introduction of novel agents has resulted in impressive response rates and improved survival in patients with lymphoid malignancies.  Integrating their use into clinical practice with transplant has both optimized the use and benefits of transplants and has delayed the time to transplants. We are still trying to understand how best to use these drugs.  Unfortunately costs will remain a factor.

Questions that continue to be pertinent & worth investigation regarding transplantation in today’s Canadian landscape include:

  • Will transplantation be necessary with the availability of these new drug or future drugs?
  • Can transplant be delayed?
  • What is the best timing (too early vs too late)
  • Can transplant be improved?